Finally, we assessed anti-PD-1 treatment antibody binding to the original patient tumor tissue by immunofluorescence (Fig. S7C in Supplementary Material), which indicated the presence of immunotherapy binding sites, presumably PD-1 receptors. Here, PDCD1 is linked to neoplasm.